Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold?
Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant have gained 21.1% year to date against the industry 's decline of 4.7%. The stock has outperformed the sector and the S&P 500 Index in this timeframe.
Gilead Outperforms Industry, Sector & S&P 500 Index
Gilead Sciences is a dominant player in the HIV market with market-leading treatments. Its diverse portfolio also includes drugs for liver, hematology/oncology and inflammation/respiratory diseases.
Approval of new drugs, encouraging pipeline progress and positive data readouts have boosted investors' sentiment in the past six months. However, the oncology business is under pressure.
Let's delve into GILD's strengths and weaknesses to analyze how to play the stock at present.
GILD's Leading HIV Franchise Will Continue Its Momentum
Gilead's flagship drug, Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg, BIC/FTC/TAF), for HIV-1 infection has become the number-one prescribed regimen for both treatment-naïve and switch patients. Biktarvy accounts for over 51% share of the treatment market in the United States and should maintain momentum for GILD in the upcoming quarters.
Descovy (FTC 200 mg/TAF 25 mg) for pre-exposure prophylaxis (PrEP) is also witnessing good uptake. It maintains over 40% market share in the PrEP market in the United States.
Gilead's efforts to innovate its HIV portfolio are impressive. Late-stage studies, PURPOSE 1 and PURPOSE 2, validated lenacapavir's potential to prevent HIV. The FDA accepted new drug application submissions for twice-yearly lenacapavir for HIV prevention under priority review, with a target action date of June 19, 2025.
The European Medicines Agency validated the Marketing Authorization Application and EU-Medicines for All application for twice-yearly lenacapavir for HIV prevention.
The successful development and potential approval of lenacapavir for the prevention of the disease should solidify Gilead's HIV franchise.
Per GILD, lenacapavir, with its twice-yearly dosing, could set a new bar for HIV prevention and allow PrEP to reach a larger number of people who could benefit from a prevention regimen.
Livdelzi Approval Strengthens GILD's Liver Disease Portfolio
The FDA approval of seladelpar for the treatment of primary biliary cholangitis (PBC) has strengthened GILD's liver disease portfolio and validated its CymaBay acquisition. The drug's initial uptake is encouraging.
The candidate was approved under the brand name Livdelzi. Gilead also recently received conditional marketing authorization from the European Commission for seladelpar for the treatment of PBC.
Challenges for GILD's Oncology Business
Gilead's oncology portfolio, comprising the Cell Therapy franchise and breast cancer drug Trodelvy, has diversified its overall business. However, the Cell Therapy franchise, comprising Yescarta and Tecartus, is currently under pressure due to competitive headwinds in the United States and Europe that are expected to continue in 2025.
Breast cancer drug Trodelvy's sales were lower than expected in the first quarter due to inventory dynamics.
Gilead announced positive top-line results from the phase III ASCENT-03 study on Trodelvy, which showed highly statistically significant and clinically meaningful improvement in progression-free survival in patients with first-line metastatic triple-negative breast cancer (mTNBC) who are not candidates for checkpoint inhibitors.
The potential launch of anito-cel in multiple myeloma and Trodelvy in first-line mTNBC in 2026 will strengthen the company's oncology business.
GILD's Valuation and Estimate Revision
From a valuation standpoint, GILD is expensive. According to the price/earnings ratio, GILD's shares currently trade at 13.70x forward earnings, lower than the large-cap pharma industry's average of 14.62X but higher than its mean of 10.53X.
Earnings estimates for GILD have moved north in the past 60 days. The bottom-line estimate for 2025 has increased to $7.91 from $7.87, while that for 2026 has improved to $8.39 from $8.31.
Stay Invested in GILD
Large biotech companies are generally considered safe havens for investors interested in this sector as they are well equipped to weather the uncertain macroenvironment.
GILD is one of the dominant players in the HIV market. Gilead's efforts to constantly innovate its HIV portfolio should enable it to maintain growth amid competition from GSK plc GSK. GILD has also collaborated with Merck MRK to evaluate the investigational combination of islatravir and lenacapavir for the treatment of HIV. The potential launch of lenacapavir for PrEP in 2025 will be a significant boost for the company.
Gilead's strategic deals and acquisitions to diversify its business are encouraging. However, Biktarvy sales are expected to be under pressure due to Medicare Part D redesign, which, in turn, should impact overall HIV growth.
Hence, we advise prospective investors to wait and watch how well Biktarvy and the oncology business combat the existing headwinds before making a positive investment decision. In addition, we believe investors should also wait for better entry levels.
For investors already owning the stock, it's important to note that Gilead has been consistently increasing and paying out dividends. The company declared a quarterly dividend of $0.79 per share of common stock for the second quarter of 2025. Its strong cash position (as of March 31, 2025, GILD had $7.9 billion of cash, cash equivalents and marketable debt securities) indicates that the current yield of 2.91% is sustainable.
Gilead presently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GSK PLC Sponsored ADR (GSK): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
19 minutes ago
- CBC
Canada men's head coach Marsch adds experienced Johnston, Osorio for CONCACAF Gold Cup
Veterans Alistair Johnston and Jonathan Osorio will rejoin Canada later this month for the 2025 CONCACAF Gold Cup. Both are included in Jesse Marsch's 26-man roster, which also adds goalkeeper Tom McGill and defender Kamal Miller to those held over from the 23-player Canadian Shield Tournament, which begins Saturday at 3:30 p.m. ET with No. 30 Canada hosting No. 25 Ukraine at Toronto's BMO Field. The Canadians face No. 41 Ivory Coast next Tuesday at 8:30 p.m. "We're excited to be bringing a very strong squad to the upcoming Gold Cup," Marsch said in a statement. "We're very confident in the group and are looking forward to challenging for the title." Osorio (84 caps), Johnston (53) and Millar (47) bring a combined 184 caps to the squad. Osorio could skip the Shield tournament after suffering a shoulder injury with TFC on April 30. Celtic's Johnston had been dealing with a back issue. Fulback/wingback Richie Laryea, replaced by Zorhan Bassong due to injury in the CONCACAF Nations League Final roster in March, returned to action May 31 for Toronto FC from a hamstring injury that had sidelined him since March 1 and is part of both the Shield and Gold Cup squads. Midfielder Stephen Eustaquio is included in the Gold Cup roster even though his club, Portugal's FC Porto, is involved in the FIFA Club World Cup, which runs at the same time in the United States. The hope is he will be able to rejoin Canada at some point during the Gold Cup. McGill is added as the third goalkeeper on the roster, joining Maxime Crepeau and Dayne St. Clair. Osorio most experienced player There are 12 MLS players, including two from Toronto (Laryea and Osorio), two from CF Montreal (Nathan Saliba and Joel Waterman) and three from Vancouver (Sam Adekugbe, Ali Ahmed and Jayden Nelson). The roster ranges in age from 19 for Fulham defender de Fougerolles to 32 for Osorio, the most experienced player in the group. Canada opens Gold Cup play June 17 against No. 75 Honduras in Vancouver before heading to Houston to complete Group B play against No. 90 Curacao on June 21 and No. 81 El Salvador on June 24. The 16-team Gold Cup, the championship of North and Central America and the Caribbean runs June 14 through July 6 in 13 cities (all but Vancouver in the U.S.). The field includes No. 58 Saudi Arabia as a guest team. The winner and runner-up from each of the four groups advance to the knockout stage. Canada won the Gold Cup in 2000 and was third in 2002. The Canadian men lost to the U.S. in a penalty shootout in the round of 16 last time out in 2023. Mexico has won the title seven times and finished runner-up twice. The U.S. has lifted the trophy seven times and finished second on five occasions. Canada roster Goalkeepers Maxime Crepeau, Portland Timbers (MLS) Tom McGill, Brighton & Hove Albion (England) Dayne St. Clair, Minnesota United (MLS) Defenders Sam Adekugbe, Vancouver Whitecaps (MLS) Derek Cornelius, Olympique de Marseille (France) Luc De Fougerolles, Fulham (England) Jamie Knight-Lebel, Bristol City (England) Richie Laryea, Toronto FC (MLS) Alistair Johnston, Celtic (Scotland) Kamal Miller, Portland Timbers (MLS) Niko Sigur, Hadjuk Split (Croatia) Joel Waterman, CF Montreal (MLS) Midfielders Ali Ahmed, Vancouver Whitecaps (MLS) Tajon Buchanan, Inter Milan (Italy) Mathieu Choiniere, Grasshopper Zurich (Switzerland) Stephen Eustaquio, FC Porto (Portugal) Ismael Kone, Olympique de Marseille (France) Jayden Nelson, Vancouver Whitecaps (MLS) Jonathan Osorio, Toronto FC (MLS) Nathan Saliba, CF Montreal (MLS) Jacob Shaffelburg, Nashville SC (MLS) Forwards Jonathan David, LOSC Lille (France) Promise David, Royale Union Saint-Gilloise (Belgium) Daniel Jebbison, AFC Bournemouth (England) Cyle Larin, RCD Mallorca (Spain) Tani Oluwaseyi, Minnesota United (MLS)
Globe and Mail
21 minutes ago
- Globe and Mail
Trump and Xi agree to further talks to settle trade disputes between U.S., China
U.S. President Donald Trump and Chinese leader Xi Jinping agreed to further talks between the countries to hash out differences on tariffs that have roiled the global economy, according to U.S. and Chinese summaries of their phone call on Thursday. 'There should no longer be any questions respecting the complexity of Rare Earth products,' Trump wrote on social media. 'Our respective teams will be meeting shortly at a location to be determined.' Trump and a Chinese government summary of the meeting said the leaders had invited each other to their respective countries at a future date. 'The U.S. side should take a realistic view of the progress made and withdraw the negative measures imposed on China,' the Chinese government said in a statement published by the state-run Xinhua news agency. 'Xi Jinping welcomed Trump's visit to China again, and Trump expressed his sincere gratitude.' Beijing envoy urges Ottawa to end tariffs on Chinese EVs and warns against 'Cold War mentality' The highly anticipated call came amid accusations between Washington and Beijing in recent weeks over 'rare earths' minerals in a dispute that has threatened to tear up a fragile truce in the trade war between the two biggest economies. The countries struck a 90-day deal on May 12 to roll back some of the triple-digit, tit-for-tat tariffs they had placed on each other since Trump's January inauguration. Though stocks rallied, the temporary deal did not address broader concerns that strain the bilateral relationship, from the illicit fentanyl trade to the status of democratically governed Taiwan and U.S. complaints about China's state-dominated, export-driven economic model. Since returning to the White House in January, Trump has repeatedly threatened an array of punitive measures on trading partners, only to revoke some of them at the last minute. The on-again, off-again approach has baffled world leaders and spooked business executives, who say the uncertainty has made it difficult to forecast market conditions. How a Canadian suit maker got slammed by Trump's China tariffs China's decision in April to suspend exports of a wide range of critical minerals and magnets continues to disrupt supplies needed by automakers, computer chip manufacturers and military contractors around the world. Beijing sees mineral exports as a source of leverage – halting those exports could put domestic political pressure on the Republican U.S. president if economic growth sags because companies cannot produce mineral-powered products. The 90-day deal to roll back tariffs and trade restrictions is tenuous. Trump has accused China of violating the agreement and has ordered curbs on chip design software and other shipments to China, while also doubling steel and aluminum tariffs to 50%. Beijing rejected the claim and threatened countermeasures. In recent years, the United States has identified China as its top geopolitical rival and the only country in the world able to challenge the U.S. economically and militarily. Despite this and repeated trade threats and tariff announcements, Trump has spoken admiringly of Xi, including of the Chinese leader's toughness and ability to stay in power without the term limits imposed on U.S. presidents. Trump has long pushed for a call or a meeting with Xi, but China has rejected that as not in keeping with its traditional approach of working out agreement details before the leaders talk. The U.S. president and his aides see leader-to-leader talks as vital to sort through log-jams that have vexed lower-level officials in difficult negotiations. Thursday's call came at Trump's request, China said. It's not clear when the two men last spoke. Both sides said they spoke on Jan. 17, days before Trump's inauguration and Trump has repeatedly said that he had spoken to Xi since taking office on Jan. 20. He has declined to say when any call took place or to give details of their conversation. China had said that the two leaders had not had any recent phone calls. The talks are being closely watched by investors worried that a chaotic trade war could cut into corporate earnings and disrupt supply chains in the key months before the Christmas holiday shopping season. Trump's tariffs are also the subject of ongoing litigation in U.S. courts.
Globe and Mail
21 minutes ago
- Globe and Mail
Carney and Trump holding secret talks on trade and security, U.S. envoy says
Prime Minister Mark Carney is holding direct and secret talks with U.S. President Donald Trump to iron out a framework for a trade and security agreement, says the U.S. Ambassador to Canada. Peter Hoekstra told The Globe and Mail that talks between the leaders and top cabinet ministers are being held under a cone of silence to ensure a positive outcome. The Prime Minister and the President met in the Oval Office on May 6 but there has been no indication until now that they had been holding direct negotiations. 'You have the relationship and the discussions between the President and the Prime Minister,' he said, adding 'they have had conversations, more than just the Oval Office.' 'The indications that they are talking and in communications regularly is a clear indicator to me that both sides recognize the importance and the urgency of moving this forward.' The talks include Trade Minister Dominic LeBlanc and U.S. Commerce Secretary Howard Lutnick and Trade Representative Jamieson Greer, he said. Mr. Hoekstra said the Canadians and Americans are 'laying out the perimeters' of a deal that could involve boosting U.S. content in autos, improving U.S. access to Canadian critical minerals and ensuring Canada plays a much bigger role in the Arctic. The talks also include increased defence spending, energy, border security, fentanyl as well as steel and aluminum. The current talks are solely between Canada and the U.S. and do not involve Mexico, the ambassador said. But he said the Canadians and Americans want the talks to be successful, which is why they are working hard to ensure there no leaks. 'This is too important for it be managed by leaks. There is too much at stake. You are our second largest trading partner,' he said. Mr. Hoekstra said it was entirely possible that a deal could be reached before September, something the Prime Minister alluded to last week. 'Sure, September is possible. Is possible to be earlier. Sure. Is it possible that it will be later, sure,' he said. 'When the President is ready to announce an agreement and the Prime Minister is ready to announce an agreement. That is when that will happen.' More to come
